Pre-Open Movers: Wix Gains on Activist Stake, Take-Two Falls on GTA6 Hack
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
AutoZone (AZO) PT Raised to $2,450 at Jefferies Following Earnings
September 20, 2022 7:47 AM EDTJefferies analyst Bret Jordan raised the price target on AutoZone (NYSE: AZO) to $2,450.00 (from $2,350.00) while maintaining a Buy rating.
The analyst commented, "AZO's Q4'22 comp & EPS of 6.2% & $40.51 beat our ests. (+5.0% & $38.52) and cons. (+3.4% & $38.51) as DIFM was +22.0% y/y while DIY grew 1.1% despite lapping... More
Activist Involvement in Wix.com (WIX) Can Unlock 'Meaningful Value'
September 19, 2022 10:42 AM EDT(Updated - September 19, 2022 10:45 AM EDT)
Shares of Wix.com (NASDAQ: WIX) gained 10% early Monday after activist hedge fund Starboard Value disclosed a 9% stake in the company Friday afternoon and, according to reports from Reuters, spoke to the Israel-based website building platform about improving operations.
Starboard is said to support the company's plans to become profitable and believes it can improve its margins and grow further.... More
Wedbush Stays Sidelined on bluebird bio (BLUE) But Does Sees 'some short-term benefits' for the Company Following Skysona News
September 19, 2022 9:28 AM EDTWedbush analyst David Nierengarten reiterated a Neutral rating and $9.00 price target on bluebird bio (NASDAQ: BLUE).
The analyst comments "While we believe that the approval of SKYSONA is a win for patients suffering from CALD, we see short-term benefits for BLUE. With... More
